Early data show CAR-NK cells’ potential to overcome CAR-T toxicity – and Takeda is interested
Data from 11 patients in an MD Anderson study of a cell therapy that uses natural killer (NK) cells from donors instead of patients' own T cells showed a high response rate and low toxicity. A multicenter, international Phase II study is planned.